57 Episodo

  1. How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

    Publicado: 8/7/2020

  2. Melphalan flufenamide (melflufen) + novel agents for RRMM

    Publicado: 8/7/2020

  3. Isatuximab plus KRd for high-risk NDMM

    Publicado: 24/6/2020

  4. Novel approaches in multiple myeloma: what is unique about CELMoDs?

    Publicado: 24/6/2020

  5. Hot topics in MM: quadruplets and anti-BCMA therapy

    Publicado: 24/6/2020

  6. Genomics of high-risk myeloma

    Publicado: 23/6/2020

  7. The association between the diversity of the oral microbiome and PFS

    Publicado: 22/6/2020

  8. Novel approaches in multiple myeloma: BFCR4350A

    Publicado: 18/6/2020

  9. Update from CARTITUDE-1 | What's new since ASH?

    Publicado: 8/6/2020

  10. Novel approaches in multiple myeloma: TAK-079

    Publicado: 4/6/2020

  11. Should we use KRd or VRd for patients with NDMM?

    Publicado: 4/6/2020

  12. What is the optimal treatment for bone lesions, including patients with renal insufficiency?

    Publicado: 3/6/2020

  13. Recent advances in our understanding of myeloma progression

    Publicado: 2/6/2020

  14. Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len

    Publicado: 1/6/2020

  15. How I treat elderly patients with NDMM

    Publicado: 28/5/2020

  16. Understanding resistance mechanisms to current standard of care and how to overcome them

    Publicado: 19/5/2020

  17. What is plasma cell leukemia and what are the latest advances in treatment?

    Publicado: 15/5/2020

3 / 3

Guided by an international Steering Committee of world experts in Multiple Myeloma (MM), the MM Hub is a global online resource providing key information on Multiple Myeloma for hematologists, oncologists and researchers, run in collaboration with the European School of Haematology (ESH). Our mission is to provide the latest global up-to-date clinical guidance in Multiple Myeloma, through a comprehensive coverage of evidence-based literature, drug approvals, case studies, expert opinions and international congress reports. Hosted on Acast. See acast.com/privacy for more information.

Visit the podcast's native language site